3Young RA, Ward A. Milrinone: a preliminary review of its pharmacological properties and therapeutic use[J]. Drugs. 1988,36:158
4Evans DB. Overview of cardiovascular physiologic and pharma cologic aspect of selective phosphodiesterase peak Ⅲ inhibitors [J]. Am J Cardicol, 1989, 63:9A
5Krams R, McFalls E, Giessen WJ, et al. Dose intravenous milrinone have a direct effect on dlastolic function[J] Am Heart J,1991,121:1951
6Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in sever chronic heart failure[J]. N Engl J Med, 1991,325:1468
7Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
8Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
9Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
10Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
